Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
- Questionnaire Survey of Chronic Myeloid Leukemia Patients Finds 30 Unreported ADRs: Novartis
May 13, 2014
- Nippon Kayaku Predicts Remicade Biosimilar Sales of 1.1 Billion Yen for FY2014
May 13, 2014
- MTPC Plans to Reduce Costs by 10 Billion Yen by FY2016
May 12, 2014
- FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
- Shionogi Makes Record Operating, Ordinary Profits
May 12, 2014
- LEO Pharma Takes Over Marketing Authorization to Dovonex
May 12, 2014
- Eisai to Develop Novel Inflammatory Bowel Disease Treatment with University of Tsukuba
May 12, 2014
- Kissei Aims to Maintain Non-Consolidated Sales, Launch Hyperphosphatemia Treatment: New Midterm Plan
May 12, 2014
- DSP to Execute Option Rights to Codevelop Cerebral Infarction Cell Therapy in April-Sept.
May 9, 2014
- MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
- DSP Sales Up 11.5% in FY2013; Latuda, Softer Yen Eclipse Japan Dip
May 9, 2014
- MTPC Logs 8.4% Net Profit Rise, 1.6% Sales Decline
May 9, 2014
- Takeda FY2013 Sales Up 8.6% on Buoyant Azilva, Pantoprazole
May 9, 2014
- Seikagaku to Initiate PII/III Clinical Trial of SI-614 for Treatment of Dry Eye in the US
May 9, 2014
- PII Study of Transdermal Allergic Rhinitis Treatment Confirms Significant Improvement in Primary Endpoint: Hisamitsu
May 9, 2014
- Eisai Sets Up Global Oncology and Neurology Business Units Ahead of Schedule
May 8, 2014
- Eisai Moves to Boost Global Use of Products via Emerging Market Businesses
May 8, 2014
- Suglat Tops Anterio’s "Mind Share" Ranking in GP Market in March; Xarelto Rises Sharply
May 8, 2014
- FDA Grants Priority Review to XTANDI for Add’l Indication: Astellas
May 8, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…